Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797127 | 0.78 | KDM4E (0.42) | ALDH1A1KDM4EHSD17B10TSHRHTR2C | |
| SCHEMBL9712631 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4EHSD17B10TSHRTAS1R3 | |
| SCHEMBL7303363 | 0.77 | MAPT (0.41) | ALDH1A1KDM4EHSD17B10HTR2CL3MBTL1 | |
| SCHEMBL2381283 | 0.71 | KDM4E (0.40) | ALDH1A1KDM4EHSD17B10TSHRTAS1R3 | |
| SCHEMBL9113536 | 0.71 | GRIA1 (0.42) | ALDH1A1KDM4EHSD17B10L3MBTL1MAPK1 | |
| SCHEMBL11754306 | 0.69 | ALDH1A1 (0.43) | ALDH1A1KDM4EHSD17B10TSHRTAS1R3 | |
| SCHEMBL29536407 | 0.69 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10TSHRTAS1R3 | |
| SCHEMBL1312475 | 0.69 | MAPK1 (0.36) | TSHRMAPK1 | |
| SCHEMBL2355429 | 0.69 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10TSHRTAS1R3 | |
| SCHEMBL17744214 | 0.68 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10TSHRTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755983-B1 | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-15 | — | — | EP | claimed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | claimed |
| WO-2024145662-A1 | 2-SUBSTITUTED THIAZOLE AND BENZOTHIAZOLE COMPOSITIONS AND METHODS AS DUX4 INHIBITORS | ALTAY THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024112705-A1 | BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS | ELIMA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240122179-A1 | AUXINIC HERBICIDES AND METHODS OF USE THEREOF | CORTEVA AGRISCIENCE LLC (US) | 2024-04-18 | — | — | US | disclosed |
| CN-117813004-A | Auxin herbicide and application method thereof | 科迪华农业科技有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | HOLOSMEDIC (KR) | 2024-03-28 | — | — | US | disclosed |
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4174068-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | Holosmedic (KR) | 2023-05-03 | — | — | EP | disclosed |
| WO-2005020884-A2 | NUCLEOSIDES FOR TREATMENT OF INFECTION BY CORONA VIRUSES, TOGA VIRUSES AND PICORNA VIRUSES | IDENIX (CAYMAN) LIMITED (KY) | 2005-03-10 | — | — | WO | disclosed |
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | IDENIX PHARMACEUTICALS LLC | 2005-02-10 | — | — | US | disclosed |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | GILEAD SCIENCES, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2005003147-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | disclosed |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004002999-A2 | MODIFIED 2' AND 3' -NUCLEOSIDE PRODUGS FOR TREATING FLAVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002422-A2 | 2’-C-METHYL-3’-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004003000-A2 | 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | PNP, NSUN2, RNGTT | ALDH1A1 3858/4885KDM4E 2422/4885HSD17B10 3632/4885 |
| US-20240122179-A1 | AUXINIC HERBICIDES AND METHODS OF USE THEREOF | DDT, HACL2, ALAD | ALDH1A1 353/4885KDM4E 3249/4885HSD17B10 99/4885 |
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | ALDH1A1 1882/4885KDM4E 3122/4885HSD17B10 59/4885 |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | SLC11A2, ABCC1, TSG101 | ALDH1A1 3381/4885KDM4E 3814/4885HSD17B10 1797/4885 |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | NSUN2, BCDIN3D, METTL16 | ALDH1A1 2796/4885KDM4E 148/4885HSD17B10 2957/4885 |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | ALDH1A1 2116/4885KDM4E 2799/4885HSD17B10 4458/4885 |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | ALDH1A1 2698/4885KDM4E 1216/4885HSD17B10 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.